JAK2 V617F mutation promotes pro-inflammatory cytokine release, exacerbates endothelial damage and leukocyte infiltration, and increases the risk of atherosclerosis, requiring statin lipid-lowering therapy. Here, JAK2 is linked to atherosclerosis.